GlassScriptPhysician profile
Danielle L Bosscher
NPI 1871040154
$12,242.15
in general payments reported to CMS, 2019-2025
31 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,141 · 2022: $3,393 · 2023: $2,495 · 2024: $1,559 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,419 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,418.71 |
| Education | $289.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,548.75 | 2021-2025 | Tremfya |
| Abbvie INC. | $1,631.40 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,051.84 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $888.24 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $757.09 | 2021-2023 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $727.03 | 2021-2024 | |
| Incyte Corporation | $687.83 | 2021-2025 | Opzelura |
| Genzyme Corporation | $625.32 | 2021-2024 | |
| Leo Pharma INC. | $543.13 | 2021-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $520.10 | 2022-2025 | Sotyktu |
| Amgen INC. | $448.74 | 2021-2024 | Otezla, Enbrel |
| Lilly USA, LLC | $423.74 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $354.84 | 2021-2025 | Bimzelx, Cimzia |
| Journey Medical Corporation | $199.86 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $164.98 | 2021-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $111.29 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $90.67 | 2021-2025 | Aklief, Oracea, Epsolay |
| Genentech USA, INC. | $85.68 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.80 | 2021-2025 | Cabtreo, Jublia, Siliq |
| Vyne Pharmaceuticals INC. | $41.43 | 2021 | |
| Organon LLC | $40.98 | 2025 | Vtama |
| Almirall LLC | $35.70 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.88 | 2023-2024 | Spevigo, Cyltezo |
| Dermira, INC. | $31.52 | 2021 | |
| Janssen Scientific Affairs, LLC | $29.22 | 2022 | |
| Kerecis Limited | $26.42 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Dermavant Sciences, INC. | $19.33 | 2023 | Vtama |
| Nabriva Therapeutics, Plc | $19.20 | 2022 | |
| Krystal Biotech INC | $16.88 | 2025 | Vyjuvek |
| Mimedx Group, INC. | $15.19 | 2025 | |
| Epi Health, LLC | $15.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Bosscher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.